All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

ABBVAbbVie
1Calm
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Signing up patientsPhase 2150 patientsMain results: Oct 2029
ONCBeOne Medicines
2Calm
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
Signing up patientsPhase 230 patientsMain results: Feb 28, 2028
REGNRegeneron Pharmaceuticals
5Calm
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Signing up patientsPhase 1/2387 patientsMain results: Mar 30, 2033
BMYBristol-Myers Squibb
10Calm
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Signing up patientsPhase 3850 patientsMain results: Dec 30, 2031
RCUSArcus Biosciences, Inc.
0Calm
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
FinishedPhase 2332 patientsMain results: Sep 7, 2026
AZNAstraZeneca
0Calm
Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Running, no new patientsPhase 371 patientsMain results: Jun 30, 2029
ONCBeOne Medicines
2Calm
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Not started yetPhase 1/230 patientsMain results: Apr 30, 2030
FDMT4D Molecular Therapeutics
0Calm
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Running, no new patientsPhase 3480 patientsMain results: Jun 2027
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Signing up patientsPhase 2/3960 patientsMain results: Jul 23, 2032
ABBVAbbVie
1Calm
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer
Not started yetPhase 280 patientsMain results: Aug 2031
MRKMerck Sharp & Dohme LLC
5Calm
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Signing up patientsPhase 3348 patientsMain results: Jan 24, 2028
ONCBeOne Medicines
2Calm
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Signing up patientsPhase 1/2246 patientsMain results: Nov 2026
VSTMVerastem, Inc.
12Calm
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Signing up patientsPhase 2150 patientsMain results: Jun 2027
ONCBeOne Medicines
2Calm
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Signing up patientsPhase 1/2258 patientsMain results: Nov 30, 2029
PFEPfizer
0Calm
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Running, no new patientsPhase 31,068 patientsMain results: Jan 31, 2023
MRKMerck Sharp & Dohme LLC
5Calm
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Signing up patientsPhase 3675 patientsMain results: Dec 7, 2029
SNYSanofi
0Calm
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Running, no new patientsPhase 264 patientsMain results: Apr 1, 2027
ABBVAbbVie
1Calm
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Not started yetPhase 280 patientsMain results: Dec 2031
ONCBeOne Medicines
2Calm
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
Signing up patientsPhase 31,056 patientsMain results: Apr 2029
GILDKite, A Gilead Company
1Calm
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Running, no new patientsPhase 3550 patientsMain results: May 2031
ONCBeiGene
2Calm
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Signing up patientsPhase 2200 patientsMain results: Nov 2026
AZNAstraZeneca
0Calm
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
Invite-only sign-upPhase 3214 patientsMain results: Dec 31, 2026
VRCAVerrica Pharmaceuticals Inc.
0Calm
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Running, no new patientsPhase 3302 patientsMain results: Nov 2026
ONCBeOne Medicines
2Calm
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Signing up patientsPhase 3630 patientsMain results: Sep 30, 2029
NVSNovartis Pharmaceuticals
5Calm
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Running, no new patientsPhase 1/225 patientsMain results: Jun 11, 2029